Outlook Therapeutics (OTLK)
1.34
-0.08 (5.63%)
Upcoming Events
Latest Headlines
Form EFFECT Outlook Therapeutics,
July 22, 2026 6:05 AM - SEC Filing
Form 424B3 Outlook Therapeutics,
July 21, 2026 4:37 PM - SEC Filing
Outlook Therapeutics (OTLK) files for 17.3M share offering by selling stockholders
July 17, 2026 4:09 PM - StreetInsider
Form S-3 Outlook Therapeutics,
July 17, 2026 4:06 PM - SEC Filing
Form 8-K Outlook Therapeutics, For: Jul 16
July 16, 2026 4:06 PM - SEC Filing
Form DEFA14A Outlook Therapeutics,
July 10, 2026 6:04 AM - SEC Filing
Form 8-K Outlook Therapeutics, For: Jun 26
June 26, 2026 5:30 PM - SEC Filing
Increasing unusual call option volume: OTLK EWJ AMPG LION MGNI TENB FSK CXW LASE
June 17, 2026 6:49 AM - StreetInsider
Form 8-K Outlook Therapeutics, For: Jun 16
June 16, 2026 8:46 AM - SEC Filing
FDA accepts OUTLOOK THERAPEUTICS BLA resubmission for wet AMD drug
June 16, 2026 8:02 AM - StreetInsider
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
June 16, 2026 8:02 AM - StreetInsider
Form 4 Outlook Therapeutics, For: Jun 02 Filed by: Haddadin Yezan Munther
June 3, 2026 6:03 PM - SEC Filing
Form SCHEDULE 13D/A Outlook Therapeutics, Filed by: GMS Ventures & Investments
June 1, 2026 9:31 PM - SEC Filing
Form 4 Outlook Therapeutics, For: May 28 Filed by: Sukhtian Ghiath M.
June 1, 2026 9:30 PM - SEC Filing
Form DEFA14A Outlook Therapeutics,
June 1, 2026 5:02 PM - SEC Filing
Form DEF 14A Outlook Therapeutics, For: Jul 16
June 1, 2026 5:00 PM - SEC Filing
Form 8-K Outlook Therapeutics, For: Jun 01
June 1, 2026 9:15 AM - SEC Filing
Outlook Therapeutics resubmits drug application to FDA after appeal win
June 1, 2026 8:47 AM - StreetInsider
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
June 1, 2026 8:46 AM - StreetInsider
Form 8-K Outlook Therapeutics, For: May 29
May 29, 2026 4:32 PM - SEC Filing
Form 424B5 Outlook Therapeutics,
May 29, 2026 8:30 AM - SEC Filing
Form 8-K Outlook Therapeutics, For: May 28
May 28, 2026 5:51 PM - SEC Filing
Outlook Therapeutics prices $5 million stock offering at $0.59 per share
May 28, 2026 4:00 PM - StreetInsider
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 28, 2026 4:00 PM - StreetInsider
Form 4 Outlook Therapeutics, For: May 27 Filed by: Sukhtian Faisal Ghiath
May 27, 2026 3:29 PM - SEC Filing
Form 4 Outlook Therapeutics, For: May 26 Filed by: Haddadin Yezan Munther
May 27, 2026 3:24 PM - SEC Filing
Form 4 Outlook Therapeutics, For: May 26 Filed by: THURMAN RANDY H
May 27, 2026 3:21 PM - SEC Filing
Form 4 Outlook Therapeutics, For: May 26 Filed by: HILZINGER KURT J
May 27, 2026 3:15 PM - SEC Filing
Form 8-K Outlook Therapeutics, For: May 26
May 26, 2026 7:16 AM - SEC Filing
Outlook Therapeutics wins FDA appeal for eye drug application
May 26, 2026 7:03 AM - StreetInsider
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
May 26, 2026 7:00 AM - StreetInsider
Form PRE 14A Outlook Therapeutics, For: Jul 16
May 22, 2026 5:03 PM - SEC Filing
BTIG Downgrades Outlook Therapeutics Inc. (OTLK) to Neutral
May 18, 2026 6:08 AM - StreetInsider
Form 8-K Outlook Therapeutics, For: May 15
May 18, 2026 6:03 AM - SEC Filing
Form 10-Q Outlook Therapeutics, For: Mar 31
May 15, 2026 4:36 PM - SEC Filing
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
May 15, 2026 4:05 PM - StreetInsider
Form 424B5 Outlook Therapeutics,
May 13, 2026 5:13 PM - SEC Filing
Outlook Therapeutics enters $100 million at-the-market offering agreement
May 13, 2026 4:43 PM - StreetInsider
Form 8-K Outlook Therapeutics, For: May 12
May 13, 2026 4:36 PM - SEC Filing
Form D Outlook Therapeutics,
May 7, 2026 4:30 PM - SEC Filing
Form SCHEDULE 13G Outlook Therapeutics, Filed by: INTRACOASTAL CAPITAL, LLC
April 24, 2026 5:17 PM - SEC Filing
Full Article List
